Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CONCETTA M FORCHETTI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1184656852
CMS profile
189389
Location
ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$15,350.00

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $15,350.00 6

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
EISAI INC. $12,285.00 5
Biogen, Inc. $3,065.00 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CONCETTA M FORCHETTI

NPI 1184656852 · CMS profile ID 189389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $15,350.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $2,700.0012/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013089 CMS
EISAI INC. $810.0009/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013095 CMS
EISAI INC. $2,700.0007/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926014845 CMS
EISAI INC. $4,995.0005/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013093 CMS
EISAI INC. $1,080.0005/05/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013091 CMS
Biogen, Inc. $3,065.0004/07/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923389415 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,113.42 4
PY2020 $565.00 1
PY2021 $38,624.37 33
PY2022 $15,350.00 6
PY2023 $16,660.79 32
PY2024 $39,378.02 40
PY2025 $50,287.88 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,463.90 81
PY2024 Principal investigator $630,831.36 79
PY2023 Recipient $591.95 2
PY2023 Principal investigator $1,785,779.63 92
PY2022 Recipient $10,066.00 2
PY2022 Principal investigator $1,648,640.76 51
PY2021 Recipient $1,310.44 2
PY2021 Principal investigator $1,377,364.84 65
PY2020 Recipient $2,195.35 2
PY2020 Principal investigator $1,008,121.30 81
PY2019 Recipient $294.51 1
PY2019 Principal investigator $1,007,212.44 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $5,362.00 12/26/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252573
Principal investigator 1 Janssen Research & Development, LLC $7,687.00 12/22/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252575
Principal investigator 1 Genentech, Inc. $6,033.96 12/14/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950695705
Principal investigator 1 Genentech, Inc. $12,065.76 11/15/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950701423
Principal investigator 1 Janssen Research & Development, LLC $600.00 11/14/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252571
Principal investigator 1 Genentech, Inc. $100.00 11/07/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950701429
Principal investigator 1 Janssen Research & Development, LLC $26,304.00 10/31/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252567
Principal investigator 1 Genentech, Inc. $150.00 10/11/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950695711
Principal investigator 1 Janssen Research & Development, LLC $16,283.00 10/06/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252569
Principal investigator 1 Janssen Research & Development, LLC $25.00 09/19/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252565
Principal investigator 1 Genentech, Inc. $3,852.00 09/12/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726469
Principal investigator 1 Biogen, Inc. $29,288.50 09/07/2022 Non-covered Recipient Entity
Alexian Brothers Health Systems Inc
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 927058477
Principal investigator 1 Genentech, Inc. $150.00 09/07/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726473
Principal investigator 1 Eli Lilly and Company $5,249.00 08/28/2022 Non-covered Recipient Entity
YALE UNIVERSITY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917848637
Principal investigator 1 Genentech, Inc. $13,539.42 08/16/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726479
Principal investigator 1 Janssen Research & Development, LLC $600.00 08/15/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252561
Principal investigator 1 Janssen Research & Development, LLC $55,078.00 08/15/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252563
Principal investigator 1 Eli Lilly and Company $21.00 08/11/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917820551
Principal investigator 1 Genentech, Inc. $150.00 08/05/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726485
Principal investigator 1 Genentech, Inc. $979.62 07/13/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726491
Principal investigator 1 Genentech, Inc. $500.00 07/12/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726497
Principal investigator 1 Genentech, Inc. $200.00 07/11/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950726501
Principal investigator 1 Eli Lilly and Company $414.00 07/05/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917815423
Principal investigator 1 Janssen Research & Development, LLC $12,704.00 06/27/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885252559
Principal investigator 1 Eli Lilly and Company $348,230.00 06/07/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820437
Principal investigator 1 Genentech, Inc. $200.00 06/06/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950743031
Principal investigator 1 Genentech, Inc. $200.00 05/09/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950743035
Principal investigator 1 Eli Lilly and Company $11,320.00 05/06/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820889
Recipient Eli Lilly and Company $450.00 04/29/2022 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917809559
Principal investigator 1 Eli Lilly and Company $30,904.00 04/19/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917820821
Principal investigator 1 Genentech, Inc. $50.00 04/06/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950743041
Principal investigator 1 Genentech, Inc. $250.00 04/06/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950743047
Principal investigator 1 Genentech, Inc. $33,374.70 03/09/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751783
Recipient Eli Lilly and Company $9,616.00 03/08/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917806379
Principal investigator 1 Genentech, Inc. $250.00 03/08/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751787
Principal investigator 1 Genentech, Inc. $150.00 02/17/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751793
Principal investigator 1 Genentech, Inc. $3,700.80 02/11/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751799
Principal investigator 1 Genentech, Inc. $50.00 02/10/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751805
Principal investigator 1 Genentech, Inc. $50.00 02/10/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751811
Principal investigator 1 Genentech, Inc. $50.00 02/02/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751817
Principal investigator 1 Eli Lilly and Company $1,291.00 01/31/2022 Non-covered Recipient Entity
STEVEN A DAVIS M D
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917843285
Principal investigator 1 Eli Lilly and Company $5,153.00 01/26/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820885
Principal investigator 1 Eli Lilly and Company $435.00 01/18/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917820549
Principal investigator 1 Biogen, Inc. $619,055.00 01/12/2022 Non-covered Recipient Entity
Alexian Brothers Health System
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 927059023
Principal investigator 1 Eli Lilly and Company $1,137.00 01/11/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820435
Principal investigator 1 Genentech, Inc. $963.00 01/11/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751821
Principal investigator 1 Eli Lilly and Company $4,500.00 01/10/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917820883
Principal investigator 1 Genentech, Inc. $250.00 01/07/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751827
Principal investigator 1 Eli Lilly and Company $388,691.00 01/04/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820439
Principal investigator 1 Genentech, Inc. $50.00 01/04/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751833
Principal investigator 1 Genentech, Inc. $250.00 01/04/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751839
Principal investigator 1 Genentech, Inc. $600.00 01/04/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751845
Principal investigator 1 Genentech, Inc. $150.00 01/04/2022 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 950751851